Higher BNP/NT-pro BNP Levels Stratify Prognosis Equally Well in Patients with and Without Heart Failure: a Meta-analysis

Overview

Journal ESC Heart Fail

Date 2022 Jun 30

PMID 35769032

Authors

Stefanie Hendricks

Iryna Dykun

Bastian Balcer

Matthias Totzeck

Tienush Rassaf

Amir A Mahabadi

Affiliations

Soon will be listed here.

Abstract

Aims: The initial and dynamic levels of B-type natriuretic peptide (BNP) and N-terminal-prohormone BNP (NT-proBNP) are routinely used in clinical practice to identify patients with acute and chronic heart failure. In addition, BNP/NT-proBNP levels might be useful for risk stratification in patients with and without heart failure. We performed a meta-analysis to investigate, whether the value of BNP/NT-proBNP as predictors of long-term prognosis differentiates in cohorts with and without heart failure.

Methods And Results: We systematically searched established scientific databases for studies evaluating the prognostic value of BNP or NT-proBNP. Random effect models were constructed. Data from 66 studies with overall 83 846 patients (38 studies with 46 099 patients with heart failure and 28 studies with 37 747 patients without heart failure) were included. In the analysis of the log-transformed BNP/NT-proBNP levels, an increase in natriuretic peptides by one standard deviation was associated with a 1.7-fold higher MACE rate (hazard ratio [95% confidence interval]: 1.74[1.58-1.91], P < 0.0001). The effect sizes were comparable, with a substantial overlap in the confidence intervals, when comparing studies involving patients with and without heart failure (1.75[1.54-2.0], P < 0.0001 vs. 1.74[1.47-2.06], P < 0.0001). Similar results were observed when stratifying by quartiles of BNP/NT-proBNP. In studies using pre-defined cut-off-values for BNP/NT-proBNP, elevated levels were associated with the long-term prognosis, independent of the specific cut-off value used.

Conclusions: BNP/NT-proBNP levels are predictors for adverse long-term outcome in patients with and without known heart failure. Further research is necessary to establish appropriate thresholds, especially in non-heart failure cohorts.

Citing Articles

Using Lung Ultrasound Combined With N-terminal Pro-brain Natriuretic Peptide to Differentiate Acute Heart Failure From Chronic Obstructive Pulmonary Disease and Asthma in Emergency Department Patients Experiencing Acute Shortness of Breath.

Sharma A, Kaeley N, Aravindan N, Datta S, Vasisht S Cureus. 2025; 17(1):e77171.

PMID: 39925500 PMC: 11806969. DOI: 10.7759/cureus.77171.

The Role of NT-proBNP Levels in the Diagnosis of Hypertensive Heart Disease.

Mouzarou A, Hadjigeorgiou N, Melanarkiti D, Plakomyti T Diagnostics (Basel). 2025; 15(1.

PMID: 39795641 PMC: 11719755. DOI: 10.3390/diagnostics15010113.

Comparison of Catheter Ablation in Patients with Paroxysmal Non-valvular Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction.

Zhang Z, Lin Q, Wang C, Wu K, Huang Y, Tu T Int J Med Sci. 2025; 22(2):371-382.

PMID: 39781528 PMC: 11704700. DOI: 10.7150/ijms.103170.

Obesity Paradox and the Effect of NT-proBNP on All-Cause and Cause-Specific Mortality.

Bahniwal R, Sadr N, Schinderle C, Avila C, Sill J, Qayyum R Clin Cardiol. 2024; 47(11):e70044.

PMID: 39514242 PMC: 11546245. DOI: 10.1002/clc.70044.

BNP and NT-proBNP Thresholds for the Assessment of Prognosis in Patients Without Heart Failure.

Jehn S, Mahabadi A, Pfohl C, Vogel L, Al-Rashid F, Luedike P JACC Adv. 2024; 2(10):100688.

PMID: 38938478 PMC: 11198633. DOI: 10.1016/j.jacadv.2023.100688.

References

Pimenta J, Paulo C, Gomes A, Silva S, Rocha-Goncalves F, Bettencourt P . B-type natriuretic peptide is related to cardiac function and prognosis in hospitalized patients with decompensated cirrhosis. Liver Int. 2010; 30(7):1059-66. DOI: 10.1111/j.1478-3231.2010.02266.x. View

Rutten F, Cramer M, Zuithoff N, Lammers J, Verweij W, Grobbee D . Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease. Eur J Heart Fail. 2007; 9(6-7):651-9. DOI: 10.1016/j.ejheart.2007.01.010. View

Minami Y, Kajimoto K, Sato N, Hagiwara N, Takano T, Mebazaa A . Heterogeneity of the prognostic significance of B-type natriuretic peptide levels on admission in patients hospitalized for acute heart failure syndromes. Eur J Intern Med. 2016; 31:41-9. DOI: 10.1016/j.ejim.2016.01.023. View

Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P . N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA. 2005; 293(13):1609-16. DOI: 10.1001/jama.293.13.1609. View

McKie P, Rodeheffer R, Cataliotti A, Martin F, Urban L, Mahoney D . Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension. 2006; 47(5):874-80. PMC: 2647805. DOI: 10.1161/01.HYP.0000216794.24161.8c. View

Berin R, Zafrir B, Salman N, Amir O . Single measurement of serum N-terminal pro-brain natriuretic peptide: the best predictor of long-term mortality in patients with chronic systolic heart failure. Eur J Intern Med. 2014; 25(5):458-62. DOI: 10.1016/j.ejim.2014.04.001. View

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View

Song E, Moser D, Frazier S, Heo S, Chung M, Lennie T . Depressive symptoms affect the relationship of N-terminal pro B-type natriuretic peptide to cardiac event-free survival in patients with heart failure. J Card Fail. 2010; 16(7):572-8. PMC: 2901242. DOI: 10.1016/j.cardfail.2010.01.006. View

Panagopoulou V, Deftereos S, Kossyvakis C, Raisakis K, Giannopoulos G, Bouras G . NTproBNP: an important biomarker in cardiac diseases. Curr Top Med Chem. 2013; 13(2):82-94. DOI: 10.2174/1568026611313020002. View

10.

Redfield M, Rodeheffer R, Jacobsen S, Mahoney D, Bailey K, Burnett Jr J . Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002; 40(5):976-82. DOI: 10.1016/s0735-1097(02)02059-4. View

11.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

12.

Vrtovec B, Delgado R, Zewail A, Thomas C, Richartz B, Radovancevic B . Prolonged QTc interval and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure. Circulation. 2003; 107(13):1764-9. DOI: 10.1161/01.CIR.0000057980.84624.95. View

13.

Leistner D, Klotsche J, Pieper L, Palm S, Stalla G, Lehnert H . Prognostic value of NT-pro-BNP and hs-CRP for risk stratification in primary care: results from the population-based DETECT study. Clin Res Cardiol. 2013; 102(4):259-68. DOI: 10.1007/s00392-012-0530-5. View

14.

Franke J, Frankenstein L, Schellberg D, Bajrovic A, Wolter J, Ehlermann P . Is there an additional benefit of serial NT-proBNP measurements in patients with stable chronic heart failure receiving individually optimized therapy?. Clin Res Cardiol. 2011; 100(12):1059-67. DOI: 10.1007/s00392-011-0340-1. View

15.

Whalley G, Wright S, Pearl A, Gamble G, Walsh H, Richards M . Prognostic role of echocardiography and brain natriuretic peptide in symptomatic breathless patients in the community. Eur Heart J. 2008; 29(4):509-16. DOI: 10.1093/eurheartj/ehm647. View

16.

Kubanek M, Goode K, Lanska V, Clark A, Cleland J . The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction. Eur J Heart Fail. 2009; 11(4):367-77. DOI: 10.1093/eurjhf/hfp003. View

17.

Hendricks S, Dykun I, Balcer B, Totzeck M, Rassaf T, Mahabadi A . Higher BNP/NT-pro BNP levels stratify prognosis equally well in patients with and without heart failure: a meta-analysis. ESC Heart Fail. 2022; 9(5):3198-3209. PMC: 9715818. DOI: 10.1002/ehf2.14019. View

18.

Hamaya R, Yonetsu T, Kanaji Y, Usui E, Hoshino M, Hada M . Interrelationship in the prognostic efficacy of regional coronary flow reserve, fractional flow reserve, high-sensitivity cardiac troponin-I and NT-proBNP in patients with stable coronary artery disease. Heart Vessels. 2018; 34(3):410-418. DOI: 10.1007/s00380-018-1260-z. View

19.

Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special.... Eur J Heart Fail. 2016; 18(8):891-975. DOI: 10.1002/ejhf.592. View

20.

Tello-Montoliu A, Marin F, Roldan V, Mainar L, Lopez M, Sogorb F . A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels. J Intern Med. 2007; 262(6):651-8. DOI: 10.1111/j.1365-2796.2007.01871.x. View